INFLAMASE MILD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INFLAMASE MILD (INFLAMASE MILD).
Inflammase Mild is a combination product containing hydrocortisone, a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis. It also contains benzalkonium chloride, a quaternary ammonium compound with antiseptic properties.
| Metabolism | Hydrocortisone is primarily metabolized in the liver via reduction and conjugation; benzalkonium chloride is not significantly metabolized. |
| Excretion | Renal excretion of unchanged drug (approximately 60%) and glucuronide conjugate (20%); biliary/fecal (15%). |
| Half-life | 1.5-2.5 hours; short half-life allows frequent dosing for mild inflammation. |
| Protein binding | 99% bound to albumin. |
| Volume of Distribution | 0.15-0.20 L/kg; indicates low tissue distribution, primarily intravascular. |
| Bioavailability | Oral: 75-90%; Topical: approximately 5% systemic absorption. |
| Onset of Action | Oral: 30-60 minutes; Topical: within 1 hour. |
| Duration of Action | 4-6 hours for oral; topical duration varies with formulation, typically 4-8 hours. |
| Molecular Weight | 388.46 |
N/A
| Dosage form | SOLUTION/DROPS |
| Renal impairment | N/A |
| Liver impairment | N/A |
| Pediatric use | N/A |
| Geriatric use | N/A |
| 1st trimester | Avoid unless clearly needed. Limited human data; animal studies show risk. |
| 2nd trimester | Use only if potential benefit justifies potential risk to fetus. |
| 3rd trimester | Avoid due to risk of premature closure of ductus arteriosus and oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for INFLAMASE MILD (INFLAMASE MILD).
| Placental transfer | Crosses placenta; detectable in fetal plasma. |
| Breastfeeding | Excreted in breast milk in low amounts. Use caution in nursing mothers, especially if high doses or prolonged use. |
| Lactation Rating | L2 (Safer) |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to drug or any componentHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsTreatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgeryAdvanced renal diseaseActive peptic ulcer disease or gastrointestinal bleeding
| Precautions | Prolonged use may lead to increased intraocular pressure (IOP), glaucoma, cataract formation, or secondary ocular infections., Do not use while wearing contact lenses., If symptoms persist or worsen, discontinue use and consult a physician. |
| Food/Dietary | No known food interactions. Take with or without food. |
Loading safety data…
| Teratogenic Risk | In first trimester, risk of oral clefts and cardiovascular malformations; third trimester risk of premature ductus arteriosus closure and oligohydramnios. Avoid in third trimester. |
| Fetal Monitoring | Monitor fetal echocardiography for ductus arteriosus patency; amniotic fluid index for oligohydramnios; maternal renal function and blood pressure. |
| Fertility Effects | May inhibit ovulation through prostaglandin synthesis inhibition; reversible upon discontinuation. |
| Clinical Pearls |
| This is a low-potency corticosteroid suitable for mild dermatoses. Avoid use on face, groin, or axillae due to risk of skin atrophy. Limit continuous use to 2 weeks. Do not occlude unless directed. |
| Patient Advice | Apply a thin layer to affected skin only. · Wash hands after application unless treating hands. · Do not cover the area with bandages or wraps unless instructed. · Stop use and contact doctor if condition worsens or does not improve after 7 days. · Avoid contact with eyes. |